JPRN-UMIN000010460招募中2 期
A phase II trial of combination therapy with palonosetron / dexamethasone or palonosetron / aprepitant / dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients with urothelial cancer. - A phase II trial of combination therapy with palonosetron / dexamethasone or palonosetron / aprepitant / dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients with urothelial cancer.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Receiving pimozide (MVAC or GC therapy) 2. With other sever diseases 3. Clinical suspicion or history of metastasis to brain or meninges 4. Patients who need anticonvulsants therapy 5. Ascites and/or pleural effusion to need treatment 6. Pyloric stenosis and/or intestinal obstruction 7. Vomiting, or grade 2 or higher nausea according to CTCAE ver4.0 8. History of drug allergy 9. Pregnant or lactating women or women of childbearing potential, and no birth-control 10. Patient who doesn't have ability or intention that cooperates for procedure of the study 11. Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
进行中（未招募）
2 期
A phase II study for HER2 amplified advanced solid tumors (JUPITER trial)Solid tumorsHER2, solid tumorD009369JPRN-jRCT2031180150Ikeda Sadakatsu38
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
招募中
2 期
A randomised phase II trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in second-line treatment of advaneced or recurrent gastric cancer resistant to Docetaxel/Cisplatin/TS-1 (DCS) therapyGastric CancerJPRN-UMIN000003141Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)80
未知
3 期
Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.Type 2 diabetesJPRN-jRCT2080220136KISSEI PHARMACEUTICAL CO.,LTD.